1st Patient Treated in SHAPE Trial of ATH-1017 for Parkinson’s Dementia
Athira Pharma has dosed the first patient in its Phase 2 clinical trial evaluating ATH-1017 as a treatment for…
Articles by Yedida Y Bogachkov PhD
MJFF Supporting Biomarker Test for Early Diagnosis, Patient Monitoring
Lundbeck, with support from the Michael J. Fox Foundation (MJFF), is working to develop a “state of the…
First Patient Treated in Phase 2 Trial of NE3107 for Motor Symptoms
The first patient has been treated in BioVie’s Phase 2 clinical trial assessing the impact of its investigational therapy,…
MJFF Awards 2 Bachmann-Strauss Fellowships in Dystonia Research
A new training program, the Bachmann-Strauss Fellowship in Dystonia Research aims to grow the number of researchers focused on the…
Phase 2 Trial of Oral Oligomannate Will Target Gut-Brain Axis
Green Valley Pharmaceuticals will launch a multi-center Phase 2 clinical trial to investigate its seaweed-based oral compound oligomannate in…
Sanofi, ABL Bio Join to Develop ABL301 as Potential Treatment
ABL Bio and Sanofi are working under a global licensing agreement to jointly develop ABL301 — an investigational…
$500,000 Fox Foundation Grant Goes to Yumanity’s YTX-7739 Research
Yumanity Therapeutics has been awarded a $500,000 research grant from the Michael J. Fox Foundation for Parkinson’s Research…
1st Group Enrolled in Phase 1 Trial of DA01 for Advanced Parkinson’s
BlueRock Therapeutics’ Phase 1 trial testing DA01 — an investigational therapy to restore neuron loss — has completed enrolling…
MJFF Grant Supports Work Into Potential of Sigma-2 Receptors
Cognition Therapeutics has received a grant from the Michael J. Fox Foundation (MJFF) for Parkinson’s Research to support preclinical work…
P2B001 Shows Good Efficacy, Safety With Early Parkinson’s in Phase 3 Trial
A Phase 3 clinical trial assessing P2B001 in people with early Parkinson’s disease met its primary and a key secondary…